Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial

Tools

Vermeire, Séverine, Schreiber, Stefan, Rubin, David T., D'Haens, Geert, Reinisch, Walter, Watanabe, Mamoru, Mehta, Rajiv, Roblin, Xavier, Beales, Ian, Gietka, Piotr, Hibi, Toshifumi, Hospodarskyy, Ihor, Ritter, Timothy, Genovese, Mark C., Kwon, Paul, Santermans, Eva, Le Brun, Franck-Olivier, Barron, Rahul, Masior, Tomasz and Danese, Silvio (2024) Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Gastroenterology & Hepatology. ISSN 2468-1253

Full text not available from this repository. (Request a copy)

Abstract

There is a need for efficacious therapies for patients with Crohn's disease that are better tolerated and more durable than available treatments. We aimed to evaluate the efficacy and safety of filgotinib, an oral Janus kinase 1 preferential inhibitor, for treating Crohn's disease.

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:	https://linkinghub.elsevier.com/retrieve...
Depositing User:	LivePure Connector
Date Deposited:	04 Dec 2024 01:43
Last Modified:	04 Dec 2024 01:43
URI:	https://ueaeprints.uea.ac.uk/id/eprint/97894
DOI:	10.1016/S2468-1253(24)00272-3

Actions (login required)

View Item